GlassScriptPhysician profile
Ajeeb J Titus
NPI 1124065966
$1,125.17
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $401 · 2021: $11.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $246.53 | 2019-2020 | |
| Orexo US, INC. | $142.68 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $137.42 | 2019-2020 | |
| Allergan, INC. | $129.87 | 2019-2020 | |
| Lilly USA, LLC | $86.94 | 2019-2020 | |
| Glaxosmithkline, LLC. | $61.65 | 2019-2020 | |
| Pfizer INC. | $51.61 | 2019 | |
| Scilex Pharmaceuticals INC. | $51.14 | 2019-2020 | |
| Gilead Sciences, INC. | $45.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $43.73 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $29.25 | 2020 | |
| Kaleo, INC. | $16.40 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.34 | 2019 | |
| Merck Sharp & Dohme LLC | $14.90 | 2019 | |
| Amarin Pharma, INC. | $14.70 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $13.72 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.64 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajeeb Titus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.